Next frontier in cancer: deep dive into oncolytic viruses

In this blog, we pay attention in the development of oncolytic viruses (OVs) which destroy cancer cells and leverage the host immune system to enhance the effect.

Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques

Inactivated vaccines inducing durable cross-protective responses, safety and maintaining preparedness for future seasonally emerging SARS-CoV-2 variants

Meet Pierre !

Discover the mission and daily life of Pierre, Study & Research director in Pharmaco-imaging department.

Advancing Pulmonary Fibrosis: Preclinical Readouts in Mice Models

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules

More than 30 international leading experts has developed proposals to facilitate integration of the microbiome in drug discovery and development.

Phinc & Oncodesign Services

With Oncodesign Services and Phinc, unlocking the power of PBPK prediction and ADMET experimentation for a better drug development!

Oncodesign Services x ZoBio – ITW

Follow our exciting story and stay tuned to witness the positive impact this union can have on research!

Advancing Drug Discovery through 3D Cell Models: Unveiling Novel Hits and Mechanisms

Discover our findings highlight the importance of 3D cell models in drug discovery. Download the poster!

Combitherapy in Preclinical Breast Cancer HR+/HER2- Models

Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models

This study investigated in vivosynergism between eribulin and palbociclib in a breastcancer patient-derived xenograft (PDX) model.

Oncodesign Services Acquires ZoBio

Acquisition of ZoBio, a Dutch CRO expert in biophysics-based small molecule drug discovery, by Oncodesign Services.

Oncolytic Virus Research

Oncodesign Services has been working with ViraTherapeutics GmbH, an Austrian company and subsidiary of Boehringer Ingelheim, on their oncolytic viral immunotherapy since 2018.